Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

Despite clinical approval of erlotinib, most advanced lung cancer patients are primary non-responders. Initial responders invariably develop secondary resistance, which can be accounted for by T790M-EGFR mutation in half of the relapses. We show that MET is highly expressed in lung cancer, often con...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Z, Du, R, Jiang, S, Wu, C, Barkauskas, D S, Richey, J, Molter, J, Lam, M, Flask, C, Gerson, S, Dowlati, A, Liu, L, Lee, Z, Halmos, B, Wang, Y, Kern, J A, Ma, P C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538758/
https://www.ncbi.nlm.nih.gov/pubmed/19238632
http://dx.doi.org/10.1038/sj.bjc.6604559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538758/
https://www.ncbi.nlm.nih.gov/pubmed/19238632
http://dx.doi.org/10.1038/sj.bjc.6604559

Ejemplares similares